Driver mutations such as those in CD79B, CDKN2A, MYD88, MYC, and CCND3, which are known to negatively affect the prognosis of DLBCL (36–40), were enriched in rrDLBCL. The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.